As informações fornecidas no EL7.AI são apenas para fins educacionais e informativos e não constituem aconselhamento financeiro.

Urgentestocks

Ascendis Pharma Reports Positive Two-Year Data for Achondroplasia Treatment

Detectado pela primeira vez: Mar 16, 2026, 12:19 PM

Última atualização: 9 days ago

16 artigos·16 notícias

Instrumentos Afetados

ASND

Resumo do Evento

Ascendis Pharma reported positive two-year data for achondroplasia treatment. Data from the ApproaCH trial showed consistent growth improvement in children with achondroplasia using TransCon CNP. Further improvement in body proportionality was observed during the second year of weekly treatment.

Linha do tempo

Japan Approves Dupixent as First Targeted Treatment for Bullous Pemphigoid

Mar 24, 2026, 6:16 AMImpact: 6

Anavex Life Sciences Reports Positive Long-Term Data for Alzheimer's Treatment

Mar 23, 2026, 11:49 AMImpact: 6

BridgeBio Pharma to Present Long-Term Acoramidis Data at ACC Scientific Sessions

Mar 23, 2026, 11:49 AMImpact: 6

Insmed Reports Positive Phase 3 Results for ARIKAYCE Lung Disease Treatment

Mar 23, 2026, 11:24 AMImpact: 8

Ocugen Reports Positive 12-Month Phase 2 Data for OCU410 Gene Therapy

Mar 23, 2026, 11:17 AMImpact: 6

Vaxcyte Announces Publication of Positive Phase 1/2 Data for VAX-31 Vaccine in The Lancet

Mar 18, 2026, 11:46 PMImpact: 6